NCT02143739

Brief Summary

The primary objective of the NIS is to evaluate the severity of newly diagnosed asthma patients based on Global Initiative for Asthma (GINA) severity category (GINA 2006 update).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4,817

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2014

Typical duration for all trials

Geographic Reach
1 country

30 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 19, 2014

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 21, 2014

Completed
17 days until next milestone

Study Start

First participant enrolled

June 7, 2014

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 15, 2016

Completed
Last Updated

September 15, 2017

Status Verified

September 1, 2017

Enrollment Period

2.3 years

First QC Date

May 19, 2014

Last Update Submit

September 14, 2017

Conditions

Keywords

asthma

Outcome Measures

Primary Outcomes (1)

  • Asthma Severity assessment based on GINA definition (GINA 2006 update) at baseline in the total population

    severity based on GINA definition (GINA 2006 update) at baseline in the total population.

    Day 1

Secondary Outcomes (1)

  • evaluate the control level of initial 12 weeks treatment based on Assessment of Current Clinical Control in GINA (GINA 2012 update).

    up to 3 months

Study Arms (1)

Newly diagnosed asthma patients

The patient population will be outpatients, men or women, ≥18 years of age, Newly diagnosed asthma patients who are not on inhaled gluococorticosteroid within 3 months.The patient population should not have COPD(chronic obstructive pulmonary diseases) history, or asthma exacerbation.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

The patient population will be outpatients, men or women, ≥18 years of age, Newly diagnosed asthma patients who are not on inhaled gluococorticosteroid within 3 months.The patient population should not have COPD history, or asthma exacerbation.

You may qualify if:

  • Newly diagnosed asthma patients who are not on inhaled gluococorticosteroid within 3 months.
  • Out-patient with an age of 18 years and above
  • Signed and dated informed consent The prescription of the medicinal product is clearly separated from the decision to include the subject in the NIS. Generally, asthma medication refers to those recommended in GINA guideline (GINA2012 update) and decided by investigator.

You may not qualify if:

  • Participating in any clinical trial during the last 90 days
  • Have COPD
  • With asthma exacerbation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (30)

Research Site

Baotou, China

Location

Research Site

Beijing, China

Location

Research Site

Changsha, China

Location

Research Site

Changshu, China

Location

Research Site

Chengdu, China

Location

Research Site

Chongqing, China

Location

Research Site

Dalian, China

Location

Research Site

Daping, China

Location

Research Site

Fuzhou, China

Location

Research Site

Guangyuan, China

Location

Research Site

Guangzhou, China

Location

Research Site

Harbin, China

Location

Research Site

Hefei, China

Location

Research Site

Hohhot, China

Location

Research Site

Jining, China

Location

Research Site

Kunming, China

Location

Research Site

Mianyang, China

Location

Research Site

Nantong, China

Location

Research Site

Qingdao, China

Location

Research Site

Shanghai, China

Location

Research Site

Shenyang, China

Location

Research Site

Shenzhen, China

Location

Research Site

Shijiazhuang, China

Location

Research Site

Suining, China

Location

Research Site

Suzhou, China

Location

Research Site

Taiyuan, China

Location

Research Site

Tianjin, China

Location

Research Site

Wuhan, China

Location

Research Site

Xi'an, China

Location

Research Site

Zhengzhou, China

Location

Related Publications (7)

  • Lin JT, Chen P, Zhou X, Sun TY, Xie CM, Xiu QY, Yao WZ, Yang L, Yin KS, Zhang YM. Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma. Chin Med J (Engl). 2012 Sep;125(17):2994-3001.

    PMID: 22932169BACKGROUND
  • Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000 Nov;16(5):802-7. doi: 10.1183/09031936.00.16580200.

    PMID: 11153575BACKGROUND
  • Thompson PJ, Salvi S, Lin J, Cho YJ, Eng P, Abdul Manap R, Boonsawat W, Hsu JY, Faruqi RA, Moreno-Cantu JJ, Fish JE, Ho JC. Insights, attitudes and perceptions about asthma and its treatment: findings from a multinational survey of patients from 8 Asia-Pacific countries and Hong Kong. Respirology. 2013 Aug;18(6):957-67. doi: 10.1111/resp.12137.

    PMID: 23730953BACKGROUND
  • Zhao J; National Parents of Asthmatic Children KAP Project Team. [Asthma control status in children and related factors in 29 cities of China]. Zhonghua Er Ke Za Zhi. 2013 Feb;51(2):90-5. Chinese.

    PMID: 23527968BACKGROUND
  • Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999 Oct;14(4):902-7. doi: 10.1034/j.1399-3003.1999.14d29.x.

  • Juniper EF, O'Byrne PM, Roberts JN. Measuring asthma control in group studies: do we need airway calibre and rescue beta2-agonist use? Respir Med. 2001 May;95(5):319-23. doi: 10.1053/rmed.2001.1034.

  • Lin J, Fu X, Jiang P, Song W, Hu X, Jie Z, Liu C, He Z, Zhou X, Tang H. INITIAL - An observational study of disease severity in newly diagnosed asthma patients and initial response following 12 weeks' treatment. Sci Rep. 2019 Feb 4;9(1):1254. doi: 10.1038/s41598-018-36611-w.

Related Links

MeSH Terms

Conditions

Asthma

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Jiangtao Lin, PhD

    China-Japan Friendship Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
12 Weeks
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 19, 2014

First Posted

May 21, 2014

Study Start

June 7, 2014

Primary Completion

September 15, 2016

Study Completion

September 15, 2016

Last Updated

September 15, 2017

Record last verified: 2017-09

Locations